Chlamydia infections

Under 30 and sexually active? It's a good idea to get tested for chlamydia and gonorrhea

Retrieved on: 
Monday, April 19, 2021
Medical specialties, Sexually transmitted diseases and infections, Infectious causes of cancer, Gonorrhea, Mycoplasma, Clinical medicine, Medicine, Chlamydia infections, Chlamydia, Pelvic inflammatory disease, Preventive healthcare, Infertility

Without treatment, these infections can lead to pelvic inflammatory disease, pain and possibly infertility.\n"If people are under 30 and sexually active, it\'s a good idea to get tested," says Dr. Ainsley Moore, a family physician and associate clinical professor, Department of Family Medicine, McMaster University, and chair of the Task Force chlamydia and gonorrhea working group.

Key Points: 
  • Without treatment, these infections can lead to pelvic inflammatory disease, pain and possibly infertility.\n"If people are under 30 and sexually active, it\'s a good idea to get tested," says Dr. Ainsley Moore, a family physician and associate clinical professor, Department of Family Medicine, McMaster University, and chair of the Task Force chlamydia and gonorrhea working group.
  • "Many people are asymptomatic and may not seek treatment so we\'re recommending opportunistic testing, that is, at any health care visit.
  • "\nThe guideline recommends that health care providers in Canada offer routine screening (testing) for chlamydia and gonorrhea to all sexually active patients under age 30 not known to belong to a high-risk group.
  • The task force\'s mandate is to develop and disseminate evidence-based clinical practice guidelines for primary and preventive care.\n'

binx health Announces Second FDA 510(k) Clearance Of Its Molecular Point-Of-Care Infectious Disease Platform

Retrieved on: 
Thursday, April 30, 2020
RTT, Sexually transmitted diseases and infections, Infectious causes of cancer, Chlamydia infections, Chlamydia, Chlamydiae, Gonorrhea, Epidemiology, Health, Clinical medicine

Today, the Company announces FDA 510(k) clearance to market itssensitive and specific, molecular point-of-care testing platform, the binxio,for the detection of chlamydia (CT) and gonorrhea (NG)the two most tested-for STIs globallyin male urinespecimens.

Key Points: 
  • Today, the Company announces FDA 510(k) clearance to market itssensitive and specific, molecular point-of-care testing platform, the binxio,for the detection of chlamydia (CT) and gonorrhea (NG)the two most tested-for STIs globallyin male urinespecimens.
  • TheCompany previously announced, in August of 2019, FDA 510(k) clearance of the binxiofor use with clinician and self-collected vaginal swab specimens.
  • Uniquely, the binx io platform has the proven ability to rapidly detect complex infectious disease targets from bodily fluids at very high accuracy.
  • binx health brings rapid, accurate and convenient infectious disease testing to people where they live, work and shop.

binx health Announces Second FDA 510(k) Clearance Of Its Molecular Point-Of-Care Infectious Disease Platform

Retrieved on: 
Thursday, April 30, 2020
RTT, Sexually transmitted diseases and infections, Infectious causes of cancer, Chlamydia infections, Chlamydia, Chlamydiae, Gonorrhea, Epidemiology, Health, Clinical medicine

Today, the Company announces FDA 510(k) clearance to market itssensitive and specific, molecular point-of-care testing platform, the binxio,for the detection of chlamydia (CT) and gonorrhea (NG)the two most tested-for STIs globallyin male urinespecimens.

Key Points: 
  • Today, the Company announces FDA 510(k) clearance to market itssensitive and specific, molecular point-of-care testing platform, the binxio,for the detection of chlamydia (CT) and gonorrhea (NG)the two most tested-for STIs globallyin male urinespecimens.
  • TheCompany previously announced, in August of 2019, FDA 510(k) clearance of the binxiofor use with clinician and self-collected vaginal swab specimens.
  • Uniquely, the binx io platform has the proven ability to rapidly detect complex infectious disease targets from bodily fluids at very high accuracy.
  • binx health brings rapid, accurate and convenient infectious disease testing to people where they live, work and shop.

Given market demand, binx health announces launch of pre-order program for its first-of-kind rapid, molecular point-of-care platform

Retrieved on: 
Monday, January 13, 2020
Sexually transmitted diseases and infections, Infectious causes of cancer, RTT, Health, Chlamydiae, Chlamydia infections, Chlamydia, Gonorrhea, Binx, Food and Drug Administration, Epidemiology, Medical specialties

binx received FDA 510(k) clearance in August 2019 for its female offering, and is submitting a 510(k) filing for its male urine offering in Q1 2020.

Key Points: 
  • binx received FDA 510(k) clearance in August 2019 for its female offering, and is submitting a 510(k) filing for its male urine offering in Q1 2020.
  • The World Health Organization (WHO) estimates each year there are 127 million new chlamydia and 87 million new gonorrhea infections globally.
  • With CT/NG infections at record highs, and published data showing up to 40% of positive patients not returning for treatment once they leave a physician's office, the need for the binx rapid platform is acute.
  • For more information, or to pre-order, please visit binx-io.com
    binx health is the pioneer in anywhere care in women's health for consumers where they live, work and shop.

Given market demand, binx health announces launch of pre-order program for its first-of-kind rapid, molecular point-of-care platform

Retrieved on: 
Monday, January 13, 2020
Sexually transmitted diseases and infections, Infectious causes of cancer, RTT, Health, Chlamydiae, Chlamydia infections, Chlamydia, Gonorrhea, Binx, Food and Drug Administration, Epidemiology, Medical specialties

binx received FDA 510(k) clearance in August 2019 for its female offering, and is submitting a 510(k) filing for its male urine offering in Q1 2020.

Key Points: 
  • binx received FDA 510(k) clearance in August 2019 for its female offering, and is submitting a 510(k) filing for its male urine offering in Q1 2020.
  • The World Health Organization (WHO) estimates each year there are 127 million new chlamydia and 87 million new gonorrhea infections globally.
  • With CT/NG infections at record highs, and published data showing up to 40% of positive patients not returning for treatment once they leave a physician's office, the need for the binx rapid platform is acute.
  • For more information, or to pre-order, please visit binx-io.com
    binx health is the pioneer in anywhere care in women's health for consumers where they live, work and shop.

Chlamydia Infections - Pipeline Review, H2 2019 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 9, 2019
Health, Pharmaceutical, Chlamydiae, Sexually transmitted diseases and infections, Chlamydia infections, Infectious causes of cancer, Medical specialties, RTT, Chlamydia, Medicine, Health, Chlamydia research

The "Chlamydia Infections - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chlamydia Infections - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The Chlamydia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Chlamydia Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Formulate corrective measures for pipeline projects by understanding Chlamydia Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

binx health Receives CE Mark For Rapid Chlamydia And Gonorrhea Test For Mass Markets

Retrieved on: 
Wednesday, May 1, 2019
Sexually transmitted diseases and infections, RTT, Infectious causes of cancer, Chlamydiae, Chlamydia infections, Demography, Gonorrhea, Health, Binx, Reproductive health, Epidemiology

Multiplex Test Panel for binx io Point-of-Care Platform Positioned to Radically Reduce Time to Treatment, Expand Access to Care

Key Points: 
  • Multiplex Test Panel for binx io Point-of-Care Platform Positioned to Radically Reduce Time to Treatment, Expand Access to Care
    BOSTON, May 1, 2019 /PRNewswire/ --binx health, the pioneer in anywhere care today announced that its proprietary Chlamydia and Gonorrhea (CT/NG) test has received European CE Mark approval.
  • More than one million STIs are acquired worldwide every day with chlamydia and gonorrhea representing two of the most prevalent1.
  • "Achieving a 30-minute diagnostic turnaround time for two of the most common STIs is a major public health breakthrough," explains Howard Heller, MD MPH, binx health's Chief Medical Officer.
  • "Modern healthcare delivery requires tools that meet consumers' needs where they live, work and shop," said Jeffrey Luber, binx health's Chief Executive Officer.

binx health Receives CE Mark For Rapid Chlamydia And Gonorrhea Test For Mass Markets

Retrieved on: 
Wednesday, May 1, 2019
Sexually transmitted diseases and infections, RTT, Infectious causes of cancer, Chlamydiae, Chlamydia infections, Demography, Gonorrhea, Health, Binx, Reproductive health, Epidemiology

Multiplex Test Panel for binx io Point-of-Care Platform Positioned to Radically Reduce Time to Treatment, Expand Access to Care

Key Points: 
  • Multiplex Test Panel for binx io Point-of-Care Platform Positioned to Radically Reduce Time to Treatment, Expand Access to Care
    BOSTON, May 1, 2019 /PRNewswire/ --binx health, the pioneer in anywhere care today announced that its proprietary Chlamydia and Gonorrhea (CT/NG) test has received European CE Mark approval.
  • More than one million STIs are acquired worldwide every day with chlamydia and gonorrhea representing two of the most prevalent1.
  • "Achieving a 30-minute diagnostic turnaround time for two of the most common STIs is a major public health breakthrough," explains Howard Heller, MD MPH, binx health's Chief Medical Officer.
  • "Modern healthcare delivery requires tools that meet consumers' needs where they live, work and shop," said Jeffrey Luber, binx health's Chief Executive Officer.

Global Sexually Transmitted Diseases (STD) Treatment Market 2019-2023| Advances in Rapid Diagnosis of STDs to Boost Demand | Technavio

Retrieved on: 
Monday, April 22, 2019
Health, Infectious diseases, Pharmaceutical, Sexually transmitted diseases and infections, Medical specialties, Infectious diseases, RTT, Health, Infectious causes of cancer, Chlamydia infections, Chlamydiae, Sexually transmitted infection, Infection, Syphilis, HIV/AIDS

View the full release here: https://www.businesswire.com/news/home/20190422005361/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20190422005361/en/
    The global sexually transmitted diseases (STD) treatment market is expected to post a CAGR of more than 4% during the period 2019-2023 (Graphic: Business Wire)
    A key factor driving the growth of the global sexually transmitted diseases (STD) treatment market is the initiativestoincreasefundingand awareness aboutSTDs.
  • The prevalence of sexually transmitted diseases (STDs) such as chlamydia, HIV/AIDS, and syphilis is increasing at a significant rate globally.
  • This global sexually transmitted diseases (STD) treatment market 2019-2023 research report also analyzes other important trends and market drivers that will affect market growth over 2019-2023.
  • Global sexually transmitted diseases (STD) treatment market: Segmentation analysis
    This market research report segments the global sexually transmitted diseases (STD) treatment market by type (viral infections, bacterial infections, and other infections) and geographic regions (North America, Europe, Asia, and ROW).

YES Means TEST says YES to its 3rd year of successfully empowering sexually active young adults to get tested for STDs

Retrieved on: 
Tuesday, April 16, 2019
RTT, Sexually transmitted diseases and infections, Infectious causes of cancer, Medical specialties, Chlamydia infections, Chlamydiae, Health, Sexually transmitted infection, Gonorrhea, Epidemiology

And now, with rates for two lesser-known STDs on the rise, the need for testing is more urgent than ever.

Key Points: 
  • And now, with rates for two lesser-known STDs on the rise, the need for testing is more urgent than ever.
  • "As women, we need to love and respect ourselves, and that means taking responsibility for the choices we make.
  • The CDC recommends that sexually active women under age 25 get tested for chlamydia and gonorrhea every year.
  • While many clinicians test for STDs as part of a patient's regular check-up, others require the patient to request specific tests.